In the News

Metformin associated with fewer cardiovascular events than sulfonylureas after decline in kidney function

The findings from this retrospective study further support metformin as the first-line treatment to which other diabetes medications are added, even in patients who are in the early stages of chronic kidney disease, an editorial noted.

CGM improved glycemic control in type 1 diabetes with or without pump

Real-time continuous glucose monitoring (CGM), with either an insulin pump or multiple daily injections, was associated with sustained improvements in HbA1c levels compared to self-monitoring of blood glucose, according to a small randomized trial.

Among older adults with type 2 diabetes, insulin use most prevalent in those with poor health

In a longitudinal study of 21,531 patients, those in poor or intermediate health at age 75 years were more likely to use insulin than those in good health (29.4% and 27.5% versus 10.5%, respectively) and less likely to discontinue it during follow-up.

MKSAP quiz: Worsening foot pain

This month's quiz asks readers to treat a 67-year-old patient with type 2 diabetes and a two-year history of worsening pain in his feet.

Spotlight on SGLT-2 inhibitors and heart failure

The effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on heart failure, in patients with and without diabetes, were the focus of three analyses published in the past month, two on dapagliflozin and one on canagliflozin.

HbA1c targets debated, history of SGLT-2 inhibitors explained

Experts offered differing recommendations for a patient's HbA1c target in Beyond the Guidelines, while a History of Medicine article said that the risks of sodium-glucose cotransporter-2 (SGLT-2) inhibitors could have been understood sooner.

Studies show benefits of glucagon-like peptide-1 receptor agonists

A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.

In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years

These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.

First noninjection GLP-1 receptor agonist approved

The FDA has approved an oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to help improve blood glucose control in adults with type 2 diabetes.